MANIFEST-2: Pelabresib in Myelofibrosis: MOA, Study Design, and Spleen Volume Reduction

Opinion
Video

Panelists discuss the MANIFEST-2 trial of pelabresib in myelofibrosis, focusing on its mechanism of action (MOA), study design, and impact on spleen volume reduction.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
Related Content